MSD Animal Health has moved a step closer to releasing the topical parasiticide Bravecto Plus for cats into the European market.
The Madison, New Jersey, company reported March 21 that the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use “adopted a positive opinion recommending marketing authorization” for Bravecto Plus (fluralaner plus moxidectin). The final decision rests with the European Commission.
“If granted marketing approval, Bravecto Plus will be a sustained, broad-spectrum combination topical solution for cats with, or at risk from, both internal and external parasite infestations: ticks and fleas, heartworm, roundworm and hookworm,” MSD Animal Health stated.
MSD operates under the name Merck Animal Health in the United States and Canada.
The U.S. launch of Bravecto (fluralaner) tablets for dogs occurred in 2014. A spot-on formulation for dogs and cats was unveiled in 2016.
More than 60 million doses of Bravecto have been distributed in 72 countries since its release, the company stated.